Literature DB >> 10496353

Overexpression of IL-1ra gene up-regulates interleukin-1beta converting enzyme (ICE) gene expression: possible mechanism underlying IL-1beta-resistance of cancer cells.

M Sumitomo1, M Tachibana, M Murai, M Hayakawa, H Nakamura, A Takayanagi, N Shimizu.   

Abstract

We investigated the interaction of endogenous interleukin (IL)-1beta, IL-1ra, and interleukin-1beta converting enzyme (ICE) in four human urological cancer cell lines, KU-19-19, KU-1, KU-2 and KU-19-20. Northern blot analysis showed that IL-1beta gene was expressed in all cell lines. On the other hand, in KU-19-19 and KU-19-20, the gene expressions of both IL-1ra and ICE were suppressed. MTT assay revealed that IL-1beta (10 ng ml(-1)) promoted cell growth in KU-19-19 and KU-19-20, while it inhibited in KU-1 and KU-2. An ICE inhibitor, Acetyl-Tyr-Val-Ala-Asp-CHO (YVAD-CHO) blocked IL-1beta-induced growth inhibition in KU-1 and KU-2. Overexpression of the secretory type IL-1ra with adenovirus vector (AxlL-1ra) enhanced ICE gene expression, while exogenous IL-1ra (100 ng ml(-1)) did not enhance it. Furthermore, AxIL-1ra treatment promoted endogenous IL-1beta secretion and induced significant growth inhibition and apoptotic cell death on KU-19-19 and KU-19-20. Treatment with either IL-1ra (100 ng ml(-1)), IL-1beta antibody (100 microg ml(-1)), or YVAD-CHO blocked AxlL-1ra-induced cell death in KU-19-19 and KU-19-20. These results suggest that IL-1beta-sensitivity depends on the level of ICE gene expression, which is regulated by the level of endogenous slL-1ra expression. This is a first report on the intracellular function of slL-1ra and these findings may provide key insights into the mechanism underlying the viability of cancer cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10496353      PMCID: PMC2362876          DOI: 10.1038/sj.bjc.6690688

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  41 in total

Review 1.  Determination of IL1 alpha, IL1 beta and IL2 in biological media using specific enzyme immunometric assays.

Authors:  J Grassi; C J Roberge; Y Frobert; P Pradelles; P E Poubelle
Journal:  Immunol Rev       Date:  1991-02       Impact factor: 12.988

2.  Identification of a monocyte specific pre-interleukin 1 beta convertase activity.

Authors:  M J Kostura; M J Tocci; G Limjuco; J Chin; P Cameron; A G Hillman; N A Chartrain; J A Schmidt
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

3.  Pre-exposure of human B cells to recombinant IL-1 enhances subsequent proliferation.

Authors:  A S Freedman; G Freeman; J Whitman; J Segil; J Daley; L M Nadler
Journal:  J Immunol       Date:  1988-11-15       Impact factor: 5.422

4.  Extension of the life-span of human endothelial cells by an interleukin-1 alpha antisense oligomer.

Authors:  J A Maier; P Voulalas; D Roeder; T Maciag
Journal:  Science       Date:  1990-09-28       Impact factor: 47.728

5.  Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist.

Authors:  W P Arend; H G Welgus; R C Thompson; S P Eisenberg
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

6.  Lymphocyte-activating and growth-inhibitory activities for several sources of native and recombinant interleukin 1.

Authors:  E V Gaffney; S C Tsai
Journal:  Cancer Res       Date:  1986-08       Impact factor: 12.701

7.  The kinetics of interleukin 1 secretion from activated monocytes. Differences between interleukin 1 alpha and interleukin 1 beta.

Authors:  D J Hazuda; J C Lee; P R Young
Journal:  J Biol Chem       Date:  1988-06-15       Impact factor: 5.157

8.  Differences in the synthesis and kinetics of release of interleukin 1 alpha, interleukin 1 beta and tumor necrosis factor from human mononuclear cells.

Authors:  G Lonnemann; S Endres; J W Van der Meer; J G Cannon; K M Koch; C A Dinarello
Journal:  Eur J Immunol       Date:  1989-09       Impact factor: 5.532

9.  Activation of interleukin-1 beta by a co-induced protease.

Authors:  R A Black; S R Kronheim; P R Sleath
Journal:  FEBS Lett       Date:  1989-04-24       Impact factor: 4.124

10.  Constitutive production of multiple cytokines and a human chorionic gonadotrophin beta-subunit by a human bladder cancer cell line (KU-19-19): possible demonstration of totipotential differentiation.

Authors:  M Tachibana; A Miyakawa; J Nakashima; M Murai; K Nakamura; A Kubo; J I Hata
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  3 in total

1.  Treatment of fulminant hepatic failure in rats using a bioartificial liver device containing porcine hepatocytes producing interleukin-1 receptor antagonist.

Authors:  Masahiro Shinoda; Arno W Tilles; Go Wakabayashi; Atsushi Takayanagi; Hirohisa Harada; Hideaki Obara; Kazuhiro Suganuma; François Berthiaume; Motohide Shimazu; Nobuyoshi Shimizu; Masaki Kitajima; Ronald G Tompkins; Mehmet Toner; Martin L Yarmush
Journal:  Tissue Eng       Date:  2006-05

2.  A bioartificial liver device secreting interleukin-1 receptor antagonist for the treatment of hepatic failure in rats.

Authors:  Masahiro Shinoda; Arno W Tilles; Naoya Kobayashi; Go Wakabayashi; Atsushi Takayanagi; Toshinori Totsugawa; Hirohisa Harada; Hideaki Obara; Kazuhiro Suganuma; François Berthiaume; Motohide Shimazu; Nobuyoshi Shimizu; Noriaki Tanaka; Masaki Kitajima; Ronald G Tompkins; Mehmet Toner; Martin L Yarmush
Journal:  J Surg Res       Date:  2006-11-01       Impact factor: 2.192

3.  Staurosporine-induced apoptosis and hydrogen peroxide-induced necrosis in two human breast cell lines.

Authors:  A L McKeague; D J Wilson; John Nelson
Journal:  Br J Cancer       Date:  2003-01-13       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.